oleclumab,durvalumab
astrazeneca
['vance', 'durva', 'oleclumab', 'tnbc', 'increase,(-increased)', 'bcsm']
oleclumab (anti-cd73) + chemoimmunotherapy does not increase 24-wk cbr over durvalumab + chemoimmunotherapy in advanced tnbc independent of pd-l1 and cd73 status #esmo22 #bcsm 
CME experts Sara Fagerlie, PhD, CHCP & Mindy Tanzola, PhD have joined forces at Front Row to help clinicians & educators manage the oncology information deluge